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 Objectives To determine optimal perioperative antithrombotic management 
for patients with cardiac diseases undergoing joint replacement 
surgeries.
 Data sources MEDLINE and PubMed database search up to January 2013.
 Study selection Those dealing with perioperative antithrombotic management 
of patients undergoing orthopaedic operations, especially 
joint replacement, and also those undergoing general surgery. 
Various combinations of the following key words were used 
in our search: “antiplatelet”, “antithrombotic”, “anticoagulant”, 
“coronary stent”, “perioperative”, “venous thromboembolism”, 
“cardiovascular”, “surgery”, “orthopaedic”, “knee replacement”, 
“hip replacement”, “joint replacement”, and “arthroplasty”.
 Data extraction Literature review, original articles, and best practice guidelines.
 Data synthesis Patients should be stratified according to their risk of developing 
arterial thromboembolism in order to decide the most 
appropriate perioperative antiplatelet or anticoagulant regimen 
for them. After recent coronary stenting, including bare-metal 
stents implanted within 6 weeks and drug-eluting stents 
implanted within 6 months, surgery should be deferred. For 
venous thromboembolism prophylaxis in patients already on 
aspirin, the dosage should be adjusted as necessary or additional 
low-molecular-weight heparin administered.
 Conclusion The perioperative management of patients with cardiac 
diseases in receipt of antithrombotic agents is based upon 
a delicate balance between the perceived risk of arterial 
thromboembolism and the perceived risk of perioperative 
bleeding. One must exercise good judgement in deciding 
the most appropriate perioperative antithrombotic regimen. 
Venous thromboembolism is also a common problem after joint 
replacement surgeries. For patients already on aspirin, optimal 
venous thromboembolism prophylaxis is still being debated.
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Introduction
Joint replacement surgeries are a cost-effective measure to treat end-stage arthritis.1 
Nowadays, it is common for patients with cardiac diseases on antithrombotic therapy 
to undergo joint replacement surgeries. This is partly due to the ageing population and 
increasingly sedentary lifestyle of most patients. Moreover, obesity itself is a common risk 
factor for the development of both coronary heart disease and degenerative arthritis.2 
 In Queen Mary Hospital, during the period from January 2012 to December 2012, a total 
of 324 patients underwent elective primary total knee or total hip replacement surgeries. 
Among these patients, 52 (16%) were on some form of antithrombotic treatment. Of these 
52 patients, 46 (88%) were on aspirin, two (4%) on warfarin, one (2%) on clopidogrel, one 
(2%) on low-molecular-weight heparin (LMWH), and two (4%) on dual antiplatelet therapy.
 These patients pose a perioperative management dilemma to orthopaedic surgeons. 
On the one hand, there is concern about the increased risk of perioperative bleeding 
associated with continuing antithrombotic therapy.3-5 On the other hand, there is concern 
about the risk of arterial thromboembolism (ATE) that may manifest as an acute coronary 
syndrome (ACS) and/or stroke due to discontinuing these agents.6 
 Venous thromboembolism (VTE) is also a common problem after joint replacement 
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surgeries and various prophylactic measures have 
been recommended. Many of these patients are 
already on aspirin for cardiac diseases and what 
constitutes optimal VTE prophylaxis strategy for this 
group of patients is still being debated.
 We therefore set out to evaluate what might be 
optimal perioperative antithrombotic management 
for patients undergoing joint replacement surgeries. 
We also asked what could be the optimal strategy for 
the prevention of VTE in patients who are already on 
aspirin for the primary or secondary prevention of 
cardiac diseases.
Search strategy and criteria
We searched and reviewed the existing literature 
 目的 探討因心臟系統疾病須服食抗血栓藥物而將接受關節
置換手術的病人，其手術前後的最佳抗血栓藥物調校
方案。
 資料來源 於MEDLINE及PubMed資料庫搜索直至2013年1月的
文獻。
 研究選取 所有與手術前後抗血栓藥物調校方案相關的文獻，
包括將接受骨科手術，尤其是關節置換手術的有關
病人，以及將接受普通外科手術的有關病人。用
以搜索文獻的不同組合的關鍵詞為「抗血小板」
（antiplatelet）、「抗血栓」（antithrombotic）、
「抗凝」（anticoagulant）、「冠狀動脈支架」
（coronary stent）、「圍手術期」（perioperative）、
「靜脈血栓」（venous thromboembolism）、「心
血管」（cardiovascular）、「手術」（surgery）、
「骨科」（or thopaed ic）、「膝關節置換術」
（ k n e e  r e p l a c em e n t） 、 「 髖 關 節 置 換 術 」
（hip replacement）、「關節置換術」（ jo int 
replacement）及「關節成形術」（arthroplasty）。
 資料選取 文獻回顧、原創論文和常規應用指引。
 資料綜合 醫生應按動脈栓塞風險的高低而將病人分類，從而決
定手術前後抗血栓藥物最適當的調校方案。於最近曾
植入冠狀動脈支架的病人，包括於最近六星期內曾植
入裸金屬支架或於最近六個月內曾植入藥物塗層支架
的病人，應將手術期押後。至於已經服食亞士匹靈而
有需要作靜脈栓塞預防的病人，醫生可調校亞士匹靈
至合適的劑量或可額外處方低分子肝素以作靜脈栓塞
預防。
 結論 帶有心臟系統疾病須服食抗血栓藥物而將接受關節置
換手術的病人，其手術前後的抗血栓藥物調校方案的
決定是基於動脈栓塞的風險及手術期間失血風險之間
的平衡。醫生應從而決定手術前後的最佳抗血栓藥物
調校方案。靜脈栓塞也是關節置換手術後常見的問
題。對於已經服食亞士匹靈病人的最佳預防靜脈栓塞
方案，現在還未有定論。
關節置換手術前後抗血栓藥物的調校方案
relevant to our questions using the MEDLINE and 
PubMed online database up to January 2013. Various 
combinations of the following keywords were used 
in our search: “antiplatelet”, “antithrombotic”, 
“anticoagulant”, “coronary stent”, “perioperative”, 
“venous thromboembolism”, “cardiovascular”, 
“surgery”, “orthopaedic”, “knee replacement”, 
“hip replacement”, “joint replacement”, and 
“arthroplasty”.
Patients on aspirin monotherapy
Aspirin is an antiplatelet and non-steroidal anti-
inflammatory agent that works by inhibiting the 
synthesis of thromboxane A2, a potent stimulator 
of platelet aggregation by blocking the enzyme 
cyclooxygenase. It is widely used for primary and 
secondary prevention of ATE. Primary prevention 
is the implementation of certain interventions to 
prevent a healthy person from developing an illness, 
while secondary prevention refers to such measures 
to prevent progression or recurrence of a condition 
in a person already diagnosed to have had it.
  Studies have shown that aspirin increases the 
risk of perioperative bleeding, but this does not 
translate into increased morbidity and mortality. A 
meta-analysis of 474 studies including orthopaedic 
and non-orthopaedic surgeries found that the risk 
of perioperative bleeding was 1.5 times higher in 
patients on low-dose aspirin (intake of less than 300 
mg per day), but there was no significant difference 
in bleeding-related morbidity or mortality rates.4 
In two studies of patients on low-dose aspirin 
therapy undergoing proximal femoral fracture 
surgeries, patients on low-dose aspirin were shown 
to have an increased likelihood of receiving blood 
transfusions postoperatively, yet there was no 
increase in bleeding perioperatively (as measured 
by haemoglobin decrease or perioperative blood 
loss).7,8 The Pulmonary Embolism Prevention (PEP) 
trial, a randomised study involving 17 444 patients 
undergoing hip fracture surgeries and elective joint 
replacement surgeries who had low-dose aspirin 
started preoperatively for VTE prophylaxis, showed 
no difference in bleeding-related deaths between 
the low-dose aspirin and placebo groups.9 However, 
the frequency of bleeding treated with blood 
transfusions was 0.6% higher in the low-dose aspirin 
group.
 On the other hand, the risk of discontinuing 
aspirin perioperatively is well documented. Abrupt 
discontinuation of aspirin is believed to produce 
rebound prothrombotic activity.10 A meta-analysis of 
50 279 patients taking low-dose aspirin for secondary 
prevention showed that the risk of ATE after aspirin 
withdrawal was 3-fold higher than in those who 
continued taking it.6
 These studies suggest that discontinuing 
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aspirin therapy should only be considered if the risk 
of bleeding in a particular patient outweighs that 
of ATE, and therefore it seems sensible to stratify 
patients according to their risk profile.
 Indeed, in the recent 2012 guidelines published 
by the American College of Chest Physicians 
(ACCP), it is recommended that patients be stratified 
according to their risk of ATE.11 For high-risk patients, 
such as those taking aspirin for secondary prevention 
of ATE, it is recommended that it should be continued 
perioperatively. For low-risk patients, such as those 
taking aspirin for primary prevention of ATE, stopping 
aspirin 7 to 10 days before surgery is recommended,12 
this being the time needed to replenish the entire 
platelet pool.13,14 For the latter group of patients, it was 
also recommended that they resume aspirin within 24 
hours of surgery as soon as haemostasis is achieved.
 In its guidelines on prevention of VTE for 
patients, the American Academy of Orthopaedic 
Surgeons recommended discontinuing antiplatelet 
therapy prior to undergoing elective hip and knee 
replacement surgeries.15 These recommendations 
were mainly based on studies showing higher 
postoperative blood loss and higher reoperation 
rates in patients undergoing coronary artery bypass 
grafting (CABG) surgeries. However, the guidelines 
did not weigh these against the risk of ATE after 
stopping antiplatelet therapy. It is probably more 
practical to follow the ACCP guidelines regarding 
perioperative antiplatelet therapy and stratify 
patients according to their ATE risks.
Patients on clopidogrel monotherapy
Clopidogrel is another type of antiplatelet agent that 
works by antagonising ADP receptors on platelet 
cell membranes, thus blocking ADP-mediated 
platelet aggregation. It is now commonly used as an 
alternative to aspirin in the primary and secondary 
prevention of ATE. Comparing the risk of bleeding 
in those on high-dose aspirin and clopidogrel, the 
CAPRIE trial16 (involving 19 185 patients randomised 
to clopidogrel 75 mg once daily and aspirin 325 mg 
once daily) found that gastro-intestinal haemorrhage 
occurred in 2% of the clopidogrel group, and 2.7% of 
those on aspirin. Intracranial haemorrhage occurred 
in 0.4% of the clopidogrel group, and 0.5% of the 
aspirin group.16 To date, there are no such large-scale 
comparisons for low-dose aspirin versus clopidogrel.
 A few studies have examined the perioperative 
bleeding risk of patients on clopidogrel monotherapy. 
One study involving patients undergoing 
transbronchial lung biopsy showed a higher rate 
of bleeding in the clopidogrel-only group (89%) 
compared with the controls (3.4%), but there were no 
adverse clinical outcomes as all the bleeding could be 
controlled endoscopically. It was recommended that 
clopidogrel should be stopped before transbronchial 
biopsy.17 Two studies involving fracture surgeries 
both showed no differences in the rate of bleeding 
complications in patients on clopidogrel and in 
those who were not.18,19 These results show that 
continuation of clopidogrel during the perioperative 
period may be safe in some orthopaedic surgeries.
 The European Association of Cardiothoracic 
Surgery has published guidelines on the perioperative 
management of patients on clopidogrel who are 
about to undergo urgent cardiac surgery. The 
guidelines recommended stopping clopidogrel 5 to 
7 days before surgery. Currently, however, there are 
no guidelines on clopidogrel use perioperatively for 
non-cardiac surgery.
 More objective evidence is clearly needed to 
determine optimal perioperative management of 
patients receiving clopidogrel. Given the limited 
evidence currently available, it is probably sensible 
to stratify patients according to their risk of ATE (as 
for those on aspirin therapy), and then determine 
whether to continue or discontinue clopidogrel 
perioperatively. 
Patients on dual antiplatelet therapy
Nowadays, it is common for patients to receive dual 
antiplatelet therapy with aspirin and clopidogrel. In 
particular, benefits of such dual therapy have been 
demonstrated in patients with an ACS, and those 
undergoing an elective percutaneous coronary 
intervention (PCI).20
 Dual antiplatelet therapy is generally 
considered to confer a higher risk of bleeding than 
single antiplatelet therapy. The CURE study showed 
that patients who are on dual antiplatelet therapy had 
a 1% higher rate of bleeding complications than those 
on aspirin monotherapy (3.7% vs 2.7%), irrespective 
of whether they underwent surgery.21 Most of the 
data regarding perioperative bleeding with dual 
antiplatelet therapy were derived from patients 
undergoing CABG surgeries. In these studies, it was 
shown that dual antiplatelet therapy increased the 
risk of postoperative blood loss and receipt of blood 
transfusions following CABG, but there were no 
significant differences in terms of surgical mortality 
or outcomes.22-24 One study showed that patients on 
dual antiplatelet therapy who underwent vascular, 
orthopaedic, and visceral surgical procedures had a 
higher chance of receiving a blood transfusion than 
controls on monotherapy (43% vs 39%).25
 These studies suggest that dual antiplatelet 
therapy in the perioperative period increases 
postoperative bleeding rates, but does not influence 
postoperative morbidity or mortality.
 The ACCP guidelines recommend continuing 
aspirin and discontinuing clopidogrel 5 days before 
CABG.11 However, there are no up-to-date guidelines 
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for patients undergoing non-cardiac surgery. Patients 
receiving dual antiplatelet therapy usually have a 
history of ACS and a high risk of ATE; the risks of 
stopping both antiplatelet agents or even clopidogrel 
alone should be carefully balanced against the risks 
of perioperative bleeding. Close liaison with a 
cardiologist could be beneficial in devising the most 
suitable perioperative drug management plan for 
such patients. 
Patients having coronary artery stenting
Coronary artery stenting is now common in patients 
undergoing PCIs, as it has a higher success rate and 
lower restenosis rate than angioplasty alone.26 
 There are two main types of stents that are 
commonly used, namely: the bare-metal stent 
(BMS) and the drug-eluting stent (DES). The BMS 
was introduced in the early 1990s and was used 
after PCIs to prevent collapse of the coronary artery 
following balloon angioplasty. Stent placement 
causes endothelial damage of the coronary artery, 
the damaged tissues eventually undergo re-
endothelialisation, which takes approximately 
3 months.27 Frequently there is excessive re-
endothelialisation following BMS implantation, 
which leads to a high in-stent re-stenosis rate. Such 
restenosis after BMS implantation manifests as 
recurrent angina and warrants repeat revascularisation 
in 10 to 30% of patients.28 To address this issue, in the 
late 1990s the DES was devised. This stent is capable 
of preventing neointimal proliferation by releasing 
antiproliferative agents.28 This has decreased the 
need for target lesion revascularisation by as much 
as 75%.29 The downside is that it also delays the re-
endothelialisation process and thus lengthens the 
time of exposed stent struts, which act as a potent 
nidus for stent thrombosis.30 
 Stent thrombosis is a platelet-mediated process 
on exposed stent struts that lead to progressive 
platelet activation, aggregation, and eventually 
thrombus formation. Both BMS and DES are prone 
to stent thrombosis prior to re-endothelialisation 
of the coronary arteries, which usually occurs 
within the first month.31 Thus, in the vast majority 
of cases dual antiplatelet therapy is prescribed 
early after stenting to prevent stent thrombosis 
during the vulnerable period. Late (1 month to 1 
year after stenting) and very-late (more than 1 year 
after stenting) stent thrombosis is more common 
with DES use due to delayed re-endothelialisation 
and/or premature discontinuation of antiplatelet 
therapy.32,33 Furthermore, the prothrombotic and 
proinflammatory effects of surgery may predispose 
the coronary circulation to thrombosis, both at the 
site of stent placement and at other atherosclerotic 
lesions.34,35 Thus, there is a high risk of perioperative 
complications following withdrawal of antiplatelet 
therapy in patients with recently implanted stents, 
with studies showing that in these patients the 
mean perioperative mortality rates are as high as 
20 to 40%.36-38 It has therefore been recommended 
that patients with recently implanted stents should 
continue dual antiplatelet therapy in the immediate 
perioperative period.
 Furthermore, the ACCP has also recommended 
deferring elective surgery for at least 6 weeks after 
placement of a BMS and at least 6 months after 
placement of DES. In patients requiring urgent surgery 
within this time frame, the guidelines recommend 
that dual antiplatelet therapy should be continued 
perioperatively.11 The American Heart Association 
has also published guidelines in 2007 recommending 
deferment of elective surgery until at least 4 to 6 
weeks after placement of a BMS and at least 12 months 
after placement of a DES.39 If procedures involving 
high risk of bleeding that mandate discontinuing 
clopidogrel must be performed within this time 
frame, the guidelines suggest that it is reasonable to 
discontinue clopidogrel 5 to 7 days preoperatively and 
restart the drug as soon as possible postoperatively. 
Newer antiplatelet agents such as prasugrel (Effient; 
Eli Lilly, Indianapolis, US) and ticagrelor (Brilinta; 
AstraZeneca, London, UK) should be stopped 7 days 
and 3 days, respectively before surgery. Importantly, 
parenteral anticoagulants such as heparin do not 
decrease the risk of stent thrombosis and therefore 
should not be considered as substitutes for 
antiplatelet therapy. Again, it is recommended that 
the best perioperative management regimen for this 
group of at-risk patients should be discussed with a 
cardiologist.
Patients on anticoagulant therapy
Indications for chronic anticoagulation of patients 
with cardiac diseases include atrial fibrillation and the 
presence of mechanical heart valves. Warfarin is the 
most commonly used oral agent for these patients. 
Newer drugs such as dabigatran (Pradaxa; Boehringer 
Ingelheim, Germany), rivaroxaban (Xarelto; Bayer, 
Leverkusen, Germany), and apixaban (Eliquis; Pfizer 
and Bristol-Myers Squibb, New York, US) have also 
been introduced into the market and have been 
licensed for use in patients with atrial fibrillation.
 Multiple studies have shown that interruption 
of warfarin therapy is necessary to minimise 
perioperative bleeding.5,40-42 It has been shown that 
most surgical procedures can be performed safely 
if the international normalised ratio (INR) is less 
than 1.5.3,5 It has also been reported that if the INR 
is between 2 and 3 on warfarin, it almost always falls 
to less than 1.5 within 4.8 days of the last dose.43 
Therefore, ACCP guidelines recommend stopping 
warfarin 5 days before surgery and resuming 
therapy 12 to 24 hours after surgery provided there 
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is adequate haemostasis. Newer anticoagulants 
such as dabigatran, rivaroxaban, and apixaban have 
shorter half-lives than warfarin, and therefore it is 
recommended to stop these agents 1 to 4 days before 
undergoing surgery; for patients taking dabigatran, 
the duration varies depending on renal function. 
 Bridging therapy is the administration of 
heparin while warfarin is discontinued. It is used 
commonly during the perioperative period, since 
heparin has a short duration of action and its 
activity is readily reversible. Nowadays, bridging 
therapy is mainly resorted to with LMWH and only 
very infrequently with intravenous unfractionated 
heparin.44-46 The advantages of LMWH include ease 
of administration and the fact that it requires no 
monitoring, provided the patient does not have renal 
failure and is not pregnant.
 Guidelines published by the ACCP recommend 
that patients on warfarin should be stratified 
according to their risk of developing ATE.11 Risk 
stratification for chronic atrial fibrillation is based on 
the CHADS2 score, while that for mechanical heart 
valves it is based on the position and type of valve 
(Table 1). Patients are divided into low-, moderate-, 
and high-risk groups. In the low-risk group, no 
bridging therapy is recommended after stopping 
warfarin. Contrarily, in high-risk patients, bridging is 
always recommended after stopping warfarin. For the 
moderate-risk group, the decision is based on the 
individual patient- and surgery-related risk factors. 
The guidelines also recommend administering 
the last preoperative LMWH dose 24 hours before 
surgery and for non–high-bleeding-risk surgeries 
(including joint replacements) resume treatment in 
the first 24 hours after surgery.
 In the setting of total knee replacement 
surgeries, the conventional perioperative practice 
of discontinuing warfarin with or without switching 
to bridging therapy has recently been challenged. 
Concerns have been raised that bridging therapy 
results in rebound hypercoagulability after warfarin 
withdrawal,47-50 and that there are large fluctuations 
in INR when switching back to warfarin.51 Thus, 
recently there have been studies to examine whether 
it is safe to continue warfarin perioperatively without 
recourse to bridging. One retrospective study 
showed no increase in bleeding complications of 
patients who continued regular dosing of warfarin 
perioperatively, when compared with subjects who 
discontinued warfarin and switched to bridging 
therapy.51 Likewise, another recent retrospective study 
showed no increase in bleeding complications in 
patients who continued regular dosing with warfarin 
perioperatively, when compared with those not on 
warfarin therapy.52 Larger-scale studies are needed 
to justify such a change from conventional practice. 
Moreover, the rapid offset and onset of newer 
anticoagulants may obviate the need for bridging 
therapy. Nonetheless, more studies are needed to 
determine optimal perioperative management for 
patients taking newer drugs.
Venous thromboembolism prophylaxis 
for patients with cardiac disease who are 
already on aspirin
It is well known that patients undergoing joint 
replacement surgeries are at risk of developing 
VTE postoperatively. Many of these patients have 
concomitant cardiac diseases and may already be 
on aspirin. The optimal VTE prophylaxis for these 
patients is still under debate.
 The PEP trial enrolled 17 444 patients 
undergoing either total knee or hip joint replacement 
surgeries or hip fracture surgeries in the mid-1990s.9 
The results showed that compared with patients 
assigned to placebo, those randomised to low-dose 
aspirin (160 mg once daily taken for up to 35 days 
post-surgery) had a 28% relative risk reduction in 
symptomatic deep venous thrombosis (DVT), but 
there was no demonstrable benefit from aspirin 
with respect to non-fatal pulmonary embolism (PE). 
The pooled results of two studies comparing LMWH 
against aspirin in VTE prophylaxis yielded more 
asymptomatic DVT in the aspirin group, with an odds 
TABLE 1.  Guidelines published by the American College of Chest Physicians suggest risk stratification for perioperative thromboembolism
Risk stratum Indication for warfarin therapy
Mechanical heart valve Atrial fibrillation
High • Any mitral valve prosthesis
• Any caged-ball or tilting disc aortic valve prosthesis
• Recent (<6 months) stroke or transient ischaemic attack
• CHADS2 score* of 5 or 6
• Recent (<3 months) stroke or transient ischaemic attack
• Rheumatic valvular heart disease
Moderate • Bileaflet aortic valve prosthesis and one or more of 
the following risk factors: atrial fibrillation, prior stroke 
or transient ischaemic attack, hypertension, diabetes, 
congestive heart failure, age >75 years
• CHADS2 score of 3 or 4
Low • Bileaflet aortic valve prosthesis without atrial fibrillation 
and no other risk factors for stroke
• CHADS2 score of 0 to 2 (assuming no prior stroke or 
transient ischaemic attack)
* CHADS2 = congestive heart failure, hypertension, age ≥75 years, diabetes mellitus (1 point for each), and stroke or transient ischaemic attack (2 points); total 6 
points maximum
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ratio of 1.9, but there were too few patients with PE for 
meaningful comparison.53,54 These data suggest that 
aspirin is a feasible option for VTE prophylaxis, but 
overall evidence points to LMWH as the preferred 
treatment.
 Recently, the ACCP has published its ninth 
edition guidelines for VTE prophylaxis, specifically 
for patients undergoing orthopaedic surgery,55 in 
which both low-dose aspirin and LMWH were listed 
as options. It was also suggested that LMWH should 
be preferred over other medications including 
aspirin for prophylaxis of VTE, regardless of whether 
an intermittent pneumatic device was offered as 
mechanical prophylaxis. One of the authors of a review 
article also suggested that patients already on aspirin 
should have LMWH added for prophylaxis of VTE.56 
In the American Academy of Orthopaedic Surgeons 
guidelines, it was suggested that pharmacological 
agents and/or mechanical compressive devices 
should be used for the prevention of VTE.15 However, 
these did not provide guidance on the appropriate 
pharmacological agents of choice. 
 Based on the ACCP guidelines, LMWH should 
be started 12 hours or more before surgery or 12 
hours or more after surgery at a prophylactic dose 
for at least 10 to 14 days after surgery. It was also 
suggested that VTE prophylaxis be extended into 
out-patient attendance (35 days after surgery). We 
therefore recommend that patients who are already 
on low-dose aspirin increase the dosage to at least 160 
mg daily postoperatively until 35 days post-surgery 
and then resume the usual dosage. Alternatively, in 
addition to the usual aspirin treatment, prophylactic 
LMWH should be started 12 hours or more 
preoperatively, or 12 hours or more postoperatively 
and continued up to 10 to 14 days post-surgery and 
* BMS denotes bare-metal stent, DES drug-eluting stent, INR international normalised ratio, IPCD intermittent pneumatic compression device, 
LMWH low-molecular-weight heparin, and VTE venous thromboembolism
TABLE 2.  An algorithm for perioperative drug management of patients with cardiac diseases*
Patients on the 
following drugs
Risk stratification Action
Aspirin Low Stop aspirin 7-10 days before surgery, resume aspirin postoperatively as soon as 
haemostasis achieved
High Continue aspirin perioperatively
Need VTE prophylaxis Usual dosage <160 mg daily: 
(i) increase dosage to 160 mg daily postoperatively up to 35 days post-surgery then resume 
usual dosage; or 
(ii) add LMWH in addition for 10-14 days after surgery, then switch to aspirin 160 mg daily up 
to 35 days after surgery before resuming usual dosage of aspirin
Usual dosage ≥160 mg daily: 
(i) continue usual dosage of aspirin; or 
(ii) add LMWH in addition to usual dosage of aspirin
Additional use of IPCD for mechanical prophylaxis of VTE postoperatively recommended for 
all cases
Clopidogrel Low Stop clopidogrel 5-7 days before surgery, resume treatment postoperatively as soon as 
haemostasis achieved
High Continue clopidogrel postoperatively
Dual antiplatelet Usually high Consult cardiologist
Consider continuing aspirin, stopping clopidogrel 5-7 days before surgery and restarting 
treatment as soon as possible post-surgery
Recent coronary stent 
implantation
BMS Consult cardiologist
Postpone elective surgery for at least 4 weeks after stent implantation, preferably 6 weeks
DES Consult cardiologist
Postpone elective surgery for at least 6 months after stent implantation, preferably 12 months
BMS/DES + urgent 
surgery required
Consult cardiologist
Consider continuing aspirin, stopping clopidogrel 5-7 days before surgery and restarting 
therapy post-surgery as soon as possible
Anticoagulant therapy Low Stop warfarin 5 days before surgery
No bridging therapy required
Resume warfarin postoperatively as soon as haemostasis achieved
Moderate Stop warfarin 5 days before surgery
Need for bridging therapy should be based on individualised assessment
Consult cardiologist if in doubt
High Stop warfarin 5 days before surgery
Switch to bridging heparin therapy when the INR falls below the therapeutic range
Restart warfarin post-surgery as soon as haemostasis is achieved
Discontinue bridging heparin therapy when the INR is in the therapeutic range
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then switch to aspirin 160 mg daily till 35 days post-
surgery before resuming the usual dosage.
Discussion
The perioperative management of patients with 
cardiac diseases on antiplatelet or anticoagulant 
therapy undergoing joint replacement surgeries is 
based on a delicate balance between the perceived 
risk of ATE and/or VTE and the perceived risk of 
perioperative bleeding. Table 2 summarises the 
perioperative drug management approach to this 
group of patients. Patients should be stratified 
according to their risk of developing ATE to select 
the most appropriate perioperative antiplatelet 
or anticoagulant regimen. For low-risk patients, 
it is recommended that antiplatelet therapy and 
anticoagulant therapy be discontinued before 
surgery and resumed as soon as possible thereafter, 
provided there is adequate haemostasis. For high-risk 
patients, antiplatelet therapy should be continued; 
bridging therapy should be considered for those on 
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should be deferred for patients who have had recent 
implantation of coronary stents in receipt of dual 
antiplatelet therapy. For VTE prophylaxis, during 
the postoperative period these patients can receive 
either an adjusted aspirin dosage or LMWH in 
addition to their usual aspirin dosage.
 For these patients, close liaison with a 
cardiologist is essential in order to devise the most 
appropriate perioperative drug regimen, especially 
for those whose ATE risk may be difficult to determine.
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